AIM: To evaluate the efficacy and toxicity of preoperative chemoradiotherapy with capecitabine in locally advanced rectal cancer. METHODS: Between June 2004 and January 2005, 57 patients with operable, clinical stage II-III adenocarcinoma of the rectum entered the prospective phase II study. Radiation dose was 45 Gy (25x1.8 Gy). Concurrent chemotherapy with a daily dose of 1650 mg/m2 capecitabine was administered orally, divided into two equal doses per day, including weekends. Patients were evaluated weekly for acute toxicity and compliance with the protocol. Surgery was scheduled 6 weeks after the completion of the chemoradiotherapy. RESULTS: A single female patient died after receiving 27 Gy, because of pulmonary embolism. All other patients completed the preoperative chemoradiotherapy according to the protocol and a definitive operation was performed in all but one of these patients. The complete pathological response was recorded in 5 patients (9.1%). Tumor (T), lymph nodes (N), and overall downstaging rates were 40%, 52.9%, and 49.1%, respectively. Total sphincter preservation rate was 65.5% (36 out of 55 patients) and the rate in 27 patients with tumors located within 5 cm of the anal opening was 37% (10 out of 27 patients). The most frequent side-effect of the combined therapy was dermatitis (grade 3 in 19 patients). After surgery, a single patient died due to sepsis during the early perioperative period. Nonlethal perioperative complications were recorded in 24/55 patients. CONCLUSION: Preoperative chemoradiotherapy with oral capecitabine is safe and well tolerated. It has a downstaging potential and can increase the possibility for sphincter preservation surgery.
AIM: To evaluate the efficacy and toxicity of preoperative chemoradiotherapy with capecitabine in locally advanced rectal cancer. METHODS: Between June 2004 and January 2005, 57 patients with operable, clinical stage II-III adenocarcinoma of the rectum entered the prospective phase II study. Radiation dose was 45 Gy (25x1.8 Gy). Concurrent chemotherapy with a daily dose of 1650 mg/m2 capecitabine was administered orally, divided into two equal doses per day, including weekends. Patients were evaluated weekly for acute toxicity and compliance with the protocol. Surgery was scheduled 6 weeks after the completion of the chemoradiotherapy. RESULTS: A single female patient died after receiving 27 Gy, because of pulmonary embolism. All other patients completed the preoperative chemoradiotherapy according to the protocol and a definitive operation was performed in all but one of these patients. The complete pathological response was recorded in 5 patients (9.1%). Tumor (T), lymph nodes (N), and overall downstaging rates were 40%, 52.9%, and 49.1%, respectively. Total sphincter preservation rate was 65.5% (36 out of 55 patients) and the rate in 27 patients with tumors located within 5 cm of the anal opening was 37% (10 out of 27 patients). The most frequent side-effect of the combined therapy was dermatitis (grade 3 in 19 patients). After surgery, a single patient died due to sepsis during the early perioperative period. Nonlethal perioperative complications were recorded in 24/55 patients. CONCLUSION: Preoperative chemoradiotherapy with oral capecitabine is safe and well tolerated. It has a downstaging potential and can increase the possibility for sphincter preservation surgery.
Authors: P Piedbois; P Rougier; M Buyse; J Pignon; L Ryan; R Hansen; B Zee; B Weinerman; J Pater; C Leichman; J Macdonald; J Benedetti; J Lokich; J Fryer; G Brufman; R Isacson; A Laplanche; E Levy Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: M Miwa; M Ura; M Nishida; N Sawada; T Ishikawa; K Mori; N Shimma; I Umeda; H Ishitsuka Journal: Eur J Cancer Date: 1998-07 Impact factor: 9.162
Authors: Frank G A Jansman; Maarten J Postma; David van Hartskamp; Pax H B Willemse; Jacobus R B J Brouwers Journal: Clin Ther Date: 2004-04 Impact factor: 3.393
Authors: U N Vaishampayan; E Ben-Josef; P A Philip; V K Vaitkevicius; W Du; K J Levin; A F Shields Journal: Int J Radiat Oncol Biol Phys Date: 2002-07-01 Impact factor: 7.038
Authors: Manuel de las Heras; Fernando Arias; Rosario del Moral-Avila; Jaime Gómez-Millán; Encarnación Jiménez; Amadeo Wals; Jose Luis Tisaire; Ma Pino Alcantara Journal: Clin Transl Oncol Date: 2012-08-02 Impact factor: 3.405
Authors: Vaneja Velenik; Janja Ocvirk; Maja Music; Matej Bracko; Franc Anderluh; Irena Oblak; Ibrahim Edhemovic; Erik Brecelj; Mateja Kropivnik; Mirko Omejc Journal: Radiat Oncol Date: 2011-08-31 Impact factor: 3.481
Authors: Mostafa Abd Elwanis; Doaa W Maximous; Mohamed Ibrahim Elsayed; Nabiel N H Mikhail Journal: World J Surg Oncol Date: 2009-06-09 Impact factor: 2.754
Authors: Radwan Torky; Mohammed Alessa; Ho Seung Kim; Ahmed Sakr; Eman Zakarneh; Fozan Sauri; Heejin Bae; Nam Kyu Kim Journal: Ann Coloproctol Date: 2020-09-18